Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan

Abstract

BackgroundThere is a need to establish the effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in reducing COVID-19-related hopitalization of patients in Jordan. As the vaccination program accelerates, it is important to determine whether the vaccines' effectiveness (VE) has successfully reduced the number of acute cases admitted to hospital.MethodsTo determine the efficacy of Pfizer-BioNTech and Sinopharm COVID-19 vaccines among Jordanian patients admitted to Prince Hamza hospital, a single center case-control study was performed. The study analyzed the hospitalization rates of vaccinated (n = 536) and unvaccinated (n = 585) individuals across the 2-month period from February 6 to April 6, 2022. The cases were patients who tested positive for SARS-CoV-2 (“case-patients”), whilst the control group were hospital patients who did not test positive for SARS-CoV-2 (“control-patients”).ResultsThis study found that among 1,121 total participants (561 cases and 560 control), the overall vaccine effectiveness (VE) among the participants was 84% (95% Cl 79–88%). VE was higher in females (88%, 95% Cl 84–93%) than in males (77%, 95% Cl 67–84%) (p < 0.001), and it was highest in those between the ages of 18 and 28-years-old (95%, 95% CI 86–98%). For patients with pre-existing conditions, including chronic heart disease, chronic lung disease, and diabetes, VE was higher compared to patients with no comorbidities, though the difference was not statistically significant. Finally, in comparing all vaccinated participants, VE was higher for those who received the Pfizer vaccine (VE = 92%, 95% CI 88–94%) (OR 0.08, 95% CI 0.06–0.12) than for those who received the Sinopharm vaccine (VE = 67%, 95% CI 52–78%) (OR 0.33, 95% CI 0.22–0.48); (p = 0.011).ConclusionOverall, Pfizer and Sinopharm vaccines were found to be effective in limiting hospitalizations for acute cases of coronavirus among Jordanian adult's patient's cohort between February 6 and April 6, 2022, especially among patients with comorbidities.

Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study

“…The participants here predominantly received the Pfizer and Moderna vaccines, which may be particularly efficient at evoking a durable anti-RBD response. Similar observations were made by several studies, that participants who received the Sinopharm vaccine (whole virus) had lower antibody levels compared with Pfizer/Moderna vaccine (spike protein) 53 54. mRNA vaccine candidate also induces higher cellular immune responses than the recombinant protein vaccine.…”

Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study

“…Figure 2. Distribution of studies selected for the efficacy of the Sinopharm, CoronaVac, and Covaxin vaccines for the prevention of COVID-19[10,11,14,15,[29][30][31][32][34][35][36][37][40][41][42][43][44][47][48][49].…”

IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers

“…Understanding vaccine effectiveness by vaccine suppliers can guide individual choices and policy recommendations regarding the continued administration of coronavirus vaccines and subsequent boosters to provide substantial and significant protection against COVID-19 hospitalization. [14] In the present study, the participants were between 31 and 60 years of age, and 11% were older than 50 years. In line with the data from this study, another study reported that administering a booster dose of Pfizer BioNTech to adults who received a primary course of the same vaccine is associated with a major reduction in the risk of confirmed and severe disease due to COVID-19.…”

“…Understanding vaccine effectiveness by vaccine suppliers can guide individual choices and policy recommendations regarding the continued administration of coronavirus vaccines and subsequent boosters to provide substantial and significant protection against COVID-19 hospitalization. [ 14 ]…”